Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord mesenchymal stem cells + liraglutide
- Development stage
- Unknown
- Lead developer
- Diabetes Care Center of Nanjing Military Command
- Modality
- Peptides, Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Subcutaneous
01
Overview
This combination therapy consists of human umbilical cord-derived mesenchymal stem cells (UC-MSCs) and liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist. Developed by the Diabetes Care Center of Nanjing Military Command (also known as Fuzhou General Hospital), the treatment is being investigated for type 2 diabetes mellitus. The rationale for the combination is that UC-MSCs provide immunomodulatory effects and can potentially differentiate into insulin-producing cells, while liraglutide stimulates glucose-dependent insulin secretion and may enhance the survival and differentiation of the transplanted stem cells. Together, they aim to protect residual beta-cell function and improve glucose homeostasis more effectively than monotherapy.
- Other names
- UC-MSCs + liraglutideumbilical cord mesenchymal stem cell infusion with liraglutideglp-1-Diabetes Care Center of Nanjing Military Command-type 2 diabetes mellitusglp1-Diabetes Care Center of Nanjing Military Command-type 2 diabetes mellitusglp 1-Diabetes Care Center of Nanjing Military Command-type 2 diabetes mellitus
02
Targets
Beyond the preview
Go deeper on umbilical cord mesenchymal stem cells + liraglutide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord mesenchymal stem cells + liraglutide.